H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)

Blood

Volumn 97, Issue 12, 2001, Pages 3910-3918

  Schwaller, Juerg ^a,b,c,d,e   Anastasiadou, Ema ^a,b,c,d   Cain, Danielle ^a,b,c,d   Kutok, Jeff ^a,b,c,d   Wojiski, Sarah ^a,b,c,d   Williams, Ifor R ^a,b,c,d   LaStarza, Roberta ^a,b,c,d   Crescenzi, Barbara ^a,b,c,d   Sternberg, David W ^a,b,c,d   Andreasson, Patrick ^a,b,c,d   Schiavo, Roberta ^a,b,c,d   Siena, Salvatore ^a,b,c,d   Mecucci, Cristina ^a,b,c,d   Gary Gilliland, D ^a,b,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN TYROSINE KINASE;

AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE ISOLATION; GENE REARRANGEMENT; GENE SEQUENCE; H4 GENE; HUMAN; IMMUNOPHENOTYPING; LEUKEMOGENESIS; MOLECULAR CLONING; MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; THYROID PAPILLARY CARCINOMA;

EID: 0035877975     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3910     Document Type: Article

References (48)

1. Gilliland DG. Molecular genetics of human leukemia. Leukemia. 1998;12(suppl 1):S7-S12.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
3. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535-2540.
4. Eguchi M, Eguchi-Ishimae M, Tojo A, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 1999;93:1355-1365.
5. Lacronique V, Boureaux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
6. Reiter A, Schal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood. 1998;92:1735-1742.
7. Heldin CH, Ostman A, Ronnestrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998;1378:F79-F113.
8. Golub TR, Barker G, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
9. Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H. Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood. 1997;90:4271-4277.
10. Ross TS, Bernard O, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998;91:4419-4426.
11. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87:746-775.
12. Carroll M, Tomasson M, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14845-14850.
13. Ross TS, Gilliland DG. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J Biol Chem. 1999;274:22328-22336.
14. Tomasson MH, Williams IR, Hasserjian R, et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood. 1999;93:1707-1714.
15. Tomasson MH, Sternberg DW, Williams IR, et al. Fatal myeloproliferation, induced in mice by TEL/PDGFβR expresssion, depends on PDGFβR tyrosines 579/581. J Clin Invest. 2000;105:423-432.
16. Kolibaba KS, Drucker B. Protein tyrosine kinases and cancer. Biochim Biophys Acta. 1997;1333: F217-F248.
17. Bardelli A, Pugliese L, Comoglio PM. "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. Biochim Biophys Acta. 1997;1333:M41-M51.
18. Ross JS, Fletcher J. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(suppl 1):S53-S67.
19. Edery P, Eng C, Munnich A, Lyonnet S. RET in human development and oncogenesis. Bioessays. 1997;19:389-395.
20. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60:557-563.
21. Sarasin A, Bounacer A, Lepage F, Schlumberger M, Suarez HG. Mechanisms of mutagenesis in mammalian cells: application to human thyroid tumours. C R Acad Sci III. 1999;322:143-149.
22. Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A. 1992;89:1616-1620.
23. Grieco M, Cerrato A, Santoro M, Fusco A, Melillo RM, Vecchio G. Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. Oncogene. 1994;9:2531-2535.
24. Tong Q, Xing S, Jhiang SM. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J Biol Chem. 1997;272:9043-9047.
25. Siena S, Sammarrelli G, Grimoldi MG, et al. New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia. Haematologica. 1999;84:369-372.
26. Dierlamm J, Wlodarska I, Michaux L, et al. Successful use of the same slide for consecutive fluorescence in situ hybridization experiments. Genes Chromosomes Cancer. 1996;16:261-264.
27. Jossart GH, O'Brien B, Cheng JF, et al. A novel multicolor hybridization scheme applied to localization of a transcribed sequence (D10S170/H4) and deletion mapping in the thyroid cancer cell line TPC-1. Cytogenet Cell Genet. 1996;75:254-257.
28. Weber-Matthiesen K, Winkemann M, Mueller-Hermelink K, Schlegelberger B, Grote W. Simultaneous fluoresence immnophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem. 1992;40:171-175.
29. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333.
30. Sozzi G, Bongarzone I, Miozzo M, et al. Cytogenetic and molecular genetic characterization of papillary thyroid carcinomas. Genes Chromosomes Cancer. 1992;5:212-218.
31. Smanik PA, Furminger TL, Mazzaferri EL, Jhiang SM. Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma. Hum Mol Genet. 1995;4:2313-2318.
32. Viglietto G, Chiapetta G, Martinez-Tello FJ, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 1995;11:1207-1210.
33. Irusta PM, DiMaio D. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation. EMBO J. 1998;17:6912-6923.
34. Drummond-Barbosa D, Vaillancourt RR, Kazlauskas A, DiMaio D. Ligand-independent activation of the platelet-derived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling. Mol Cell Biol. 1995;15;2570-2581.
35. Valgeirsdottir S, Pakku K, Silvenoinen O, Heldin CH, Claesson-Welsh L. Activation of STAT5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF β-receptor juxtamembrane and kinase insert domains. Oncogene. 1998;16:505-516.
36. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92:3780-3792.
37. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998:92:3829-3840.
38. Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-ret protooncogene. Nature. 1996;381:785-789.
39. Treanor JJ, Goodman L, de Sauvage F, et al. Characterization of a multicomponent receptor for GDNF. Nature. 1996;382:80-83.
40. Jhiang SM, Cho JY, Furminger TL, et al. Thyroid carcinomas in RET/PTC transgenic mice. Recent Results Cancer Res. 1998;154:265-270.
41. Santoro M, Chiapetta G, Cerrato A, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1. Oncogene. 1996;13:2021-2026.
42. Sudol M. Structure and function of the WW domain. Prog Biophys Mol Biol. 1996;65:113-132.
43. Irusta PM, DiMaio D. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation. EMBO J. 1998;17:6912-6923.
44. Chen HI, Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for SRC homology 3-binding modules. Proc Natl Acad Sci U S A. 1995;92:7819-7823.
45. Staub O, Dho S, Henry P, et al. WW domains of Nedd4 bind to the proline-rich phosphotyrosine motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J. 1996;15:2371-2380.
46. Bedford MT, Chan DC, Leder P. FBP WW domains and the Abl SH3 domain bind to a specific class of proline-rich ligands. EMBO J. 1997;16:2376-2383.
47. Lu P-J, Zhou XZ, Shen M, Lu KP. Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science. 1999;283:1325-1328.
48. Kulkarni S, Heath C, Parker S, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 2000;60:3592-3598.